Riskpilot← Back to searchSign inGet full accessInfuTech Medical AB
ABActiveOrg 5590109111Södra Kungsgatan 59 1 TrWholesale of pharmaceutical and medical goods · NACE 4646Est. 20150 employees
Revenue 2025
SEK 184K
-23% vs 2024
EBITDA margin
-43.2%
+21% vs 2024
Equity ratio
10.7%
Financial strength
Net profit 2025
SEK -79K
+21% vs 2024
| Revenue | SEK 184K | -23% |
| EBITDA | SEK -79K | +21% |
| Net profit | SEK -79K | +21% |
| Total assets | SEK 206K | -34% |
| Equity | SEK 22K | -78% |
| Employees | 0 | — |
Legal name
InfuTech Medical AB
Org number
5590109111
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 april 2015
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska hantera import, export, försäljning, utbildning och teknisk support kring medicintekniska produkter och kringliggande IT- och audiovisuella system, erbjuda event- och kongressverksamhet, äga och förvalta fast egendom och värdepapper och därmed förenlig verksamhet.
Address
Södra Kungsgatan 59 1 Tr
Email
marcus.lindfors@infutechmedical.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 595 | 536 | 554 | 238 | 184 |
| Staff expenses | — | −193 | −0 | — | — |
| EBITDA | −67 | −65 | 139 | −100 | −79 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −67 | −65 | 139 | −100 | −79 |
| Net financials | — | 0 | 0 | 1 | 1 |
| Profit before tax | −67 | −65 | 139 | −100 | −79 |
| Tax | −0 | — | −3 | — | — |
| Net profit | −67 | −65 | 137 | −100 | −79 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 682 | 391 | 493 | 314 | 206 |
| Equity | 128 | 64 | 200 | 101 | 22 |
| Long-term debt | 338 | 284 | 198 | 162 | 162 |
| Short-term debt | 215 | 44 | 95 | 50 | 22 |
| Total debt | 553 | 328 | 293 | 213 | 184 |
EBITDA margin
-43.2%
This company
15.8%
Market median
-373% vs market
20212025
Equity ratio
10.7%
This company
38.2%
Market median
-72% vs market
20212025
Return on equity
-354.9%
This company
18.4%
Market median
-2029% vs market
20212025
Net profit margin
-42.8%
This company
8.1%
Market median
-628% vs market
20212025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20212025
Debt / equity
8.32×
This company
0.62×
Market median
-1242% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CE Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
PD Audit | Audit | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of InfuTech Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Eric Marcus Lindfors | Chief Executive Officer | 0 companies |
| Per Daniel Ageflod | Audit | 0 companies |
| Nanna Åsa Lindfors | Deputy Board Member | 0 companies |